Core B: Clinical Core

BU ADC临床核心（CC）进行和加强尖端阿尔茨海默病（AD）研究。 CC登记数据和受试者参与支持当地和国家临床研究。我们有 在登记册中成功地保持了大约20%的非洲裔美国人代表。CC获得 研究质量的MRI扫描登记参与者和CC研究者积极参与，并使 对国家和国际AD研究工作做出了重大贡献，包括遗传学和基因组学， 生物标志物开发、认知和功能评估以及认知神经科学。CC研究者 也为慢性病的临床描述、诊断和危险因素分析做出了重要贡献。 创伤性脑病（CTE）。我们已经完全整合了CTE的检查，重点是 CTE和AD的比较，并包括一组前国家橄榄球联盟（NFL）的球员， CC注册表。我们还将CC活动和方法与几项受资助的CTE研究相结合 隶属于CC。在下一个供资周期，协调委员会将有以下具体目标： 目的1：评价和纵向检查约425名受试者的登记研究，包括 其中：50名无主观认知主诉（SCC）的认知正常对照; 125名SCC对照; 100名 轻度认知障碍受试者; 75名轻度-中度AD痴呆受试者; 75名前NFL球员 头部反复受到撞击目标2：提供数据和来源， 参与当地和国家关于脑老化、AD谱和CTE研究的研究。 通过多学科诊断共识，对所有参与者进行研究质量诊断 两会高质量的数据将被收集并提交给国家阿尔茨海默病协调中心 （NACC）与合格的研究者共享数据。书记官处的设计是为了满足征聘需要 地方和国家的AD研究社区。目标3：以最低限度获得大脑捐赠同意 75%的登记研究参与者，并与神经病理学核心（NPC）合作，成功获得 死亡时至少90%的知情参与者的脑组织。消委会和全国人大将 检查临床病理学一致性，特别强调AD和CTE的比较。目标4。到 从登记参与者中采集血液和CSF产品。消委会将与全国人大紧密合作， 标本的收集与分析，银行和标本的分配。我们会提取DNA 基因型载脂蛋白E和提供样本，以合格的AD和CTE研究人员，国家细胞库， 阿尔茨海默病和阿尔茨海默病遗传学联盟。目标5：开展高质量的研究 对至少85%的登记研究进行MRI扫描，以支持AD和CTE相关研究。我们将上传 MRI数据发送至NACC。CC的神经成像部分将对扫描进行后处理，并将使 CC研究人员和AD和CTE研究社区的其他人可获得的数据。

The BU ADC Clinical Core (CC) conducts and enhances cutting-edge Alzheimer’s disease (AD) research. CC registry data and subject participation support local and national clinical research studies. We have successfully maintained approximately 20% African American representation in the registry. The CC obtains research-quality MRI scans on registry participants and CC investigators are actively engaged in, and make major contributions to national and international AD research endeavors, including genetics and genomics, biomarker development, cognitive and functional assessment, and cognitive neuroscience. CC investigators have also made significant contributions to the clinical description, diagnosis, and risk factor analysis of chronic traumatic encephalopathy (CTE). We have fully integrated the examination of CTE, with an emphasis on the comparison of CTE and AD, and have included a cohort of former National Football League (NFL) players in the CC registry. We also have integrated CC activities and methods with those of several funded studies of CTE affiliated with the CC. During the next funding cycle, the CC will have the following specific aims: Aim 1: To evaluate and longitudinally examine a registry of approximately 425 participants, comprised of: 50 cognitively normal controls without subjective cognitive complaints (SCC); 125 controls with SCC; 100 subjects with mild cognitive impairment; 75 subjects with mild-moderate AD dementia; and 75 former NFL players with extensive repetitive head impact exposure. Aim 2: To provide data and a source for well-characterized participants for local and national research studies on brain aging, AD spectrum, and CTE research. Research-quality diagnoses will be made on all participants through multidisciplinary diagnostic consensus conferences. High quality data will be collected and submitted to the National Alzheimer’s Coordinating Center (NACC) for data sharing with qualified investigators. The Registry was designed to meet the recruitment needs of the local and national AD research community. Aim 3: To obtain brain donation consents for a minimum of 75% of registry participants and to work with the Neuropathology Core (NPC) to successfully obtain brain tissue from a minimum of 90% of consented participants upon death. The CC and the NPC will examine clinicopathological agreements, with a special emphasis on the comparison of AD and CTE. Aim 4. To collect blood and CSF products from registry participants. The CC will work closely with the NPC to integrate the collection of specimens with the analysis, banking, and distribution of specimens. We will extract DNA and genotype APOE and provide samples to qualified AD and CTE researchers, the National Cell Repository for Alzheimer’s Disease and the Alzheimer’s Disease Genetics Consortium. Aim 5: To conduct research-quality MRI scans on a minimum of 85% of the registry to support AD- and CTE-related research. We will upload MRI data to NACC. The Neuroimaging section of the CC will conduct post-processing of scans and will make the data available to CC investigators and to others in the AD and CTE research communities.